The estimated Net Worth of Linda Marsh is at least $15.2 Milion dollars as of 17 June 2022. Ms. Marsh owns over 250,000 units of Fulgent Genetics Inc stock worth over $5,874,262 and over the last 5 years she sold FLGT stock worth over $9,250,000. In addition, she makes $120,200 as Independent Director at Fulgent Genetics Inc.
Linda has made over 2 trades of the Fulgent Genetics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 250,000 units of FLGT stock worth $9,250,000 on 17 June 2022.
The largest trade she's ever made was selling 250,000 units of Fulgent Genetics Inc stock on 17 June 2022 worth over $9,250,000. On average, Linda trades about 22,321 units every 60 days since 2019. As of 17 June 2022 she still owns at least 270,081 units of Fulgent Genetics Inc stock.
You can see the complete history of Ms. Marsh stock trades at the bottom of the page.
Linda Marsh serves as Independent Director of the Company. Ms. Marsh has been a member of the Board of Directors of Apollo Medical Holdings, Inc. since January 2019, and she is currently the Senior Executive Vice President of AHMC Healthcare Inc. (“AHMC Healthcare”), a fully-integrated hospital health system in Southern California with over 1,200 acute care beds and over 7,000 employees. Ms. Marsh joined AHMC Healthcare in 1999 and oversees all financial matters for seven acute care hospitals: San Gabriel Valley Medical Center, Garfield Medical Center, Anaheim Regional Medical Center, Whittier Hospital Medical Center, Alhambra Hospital, Monterey Park Hospital and Greater El Monte Community Hospital. Additionally, Ms. Marsh is responsible for all federal, state and local government relations, as well as all risk management activities. Ms. Marsh is a Board member of the Hospital Association of Southern California, a Board member of Private Essential Access Community Hospitals and also a Board member of the American Red Cross. Ms. Marsh is also an active member in the Healthcare Financial Management Association. In addition, Ms. Marsh chairs or is a participating member of numerous hospital governing boards, hospital committees and community organizations. Ms. Marsh received a Bachelor of Science degree in Economics and a Master’s degree in Accounting from the University of Southern California. Ms. Marsh also completed a Healthcare Executive Program at the University of Colorado.
As the Independent Director of Fulgent Genetics Inc, the total compensation of Linda Marsh at Fulgent Genetics Inc is $120,200. There are 7 executives at Fulgent Genetics Inc getting paid more, with Paul Kim having the highest compensation of $823,481.
Linda Marsh is 70, she's been the Independent Director of Fulgent Genetics Inc since 2019. There are 1 older and 9 younger executives at Fulgent Genetics Inc. The oldest executive at Fulgent Genetics Inc is John Bolger, 73, who is the Independent Director.
Linda's mailing address filed with the SEC is C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVENUE, EL MONTE, CA, 91731.
Over the last 9 years, insiders at Fulgent Genetics Inc have traded over $32,817,108 worth of Fulgent Genetics Inc stock and bought 1,136,382 units worth $9,558,758 . The most active insiders traders include Hanlin Gao, Ming Hsieh oraz Paul Kim. On average, Fulgent Genetics Inc executives and independent directors trade stock every 28 days with the average trade being worth of $848,250. The most recent stock trade was executed by Paul Kim on 3 September 2024, trading 1,674 units of FLGT stock currently worth $36,761.
mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
Fulgent Genetics Inc executives and other stock owners filed with the SEC include: